{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T21:56:42Z","timestamp":1773611802466,"version":"3.50.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100014569","name":"Sociedad Espa\u00f1ola de Farmacia Hospitalaria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014569","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AFinf Working Group"},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Development Regional Fund"},{"name":"Subprograma Miguel Servet","award":["CP19\/00159"],"award-info":[{"award-number":["CP19\/00159"]}]},{"name":"Subprograma Juan Rod\u00e9s","award":["JR22\/00049"],"award-info":[{"award-number":["JR22\/00049"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Temocillin is an interesting alternative to carbapenems for susceptible Enterobacteriaceae. Although its use in outpatient parenteral antimicrobial therapy (OPAT) programmes has generated interest, this has been hampered by the lack of stability data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The purpose of the present study was to evaluate the physical and chemical stability of temocillin at the recommended dose for its use in OPAT programmes, contained in polypropylene infusion bags or polyisoprene elastomeric devices at different temperatures, and to describe a novel LC-MS\/MS developed for the quantification of temocillin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Temocillin daily dose (6 g) was diluted in 500 mL of 0.9% sodium chloride to obtain a final concentration of 12 g\/L. This solution was stored at 4\u00b0C, 25\u00b0C, 32\u00b0C and 37\u00b0C for 72 h, both in polypropylene infusion bags and in polyisoprene elastomeric pumps. Physical and chemical stability were evaluated during 72 h after manufacturing. Solutions were considered stable if colour, clearness and pH remained unchanged and if the percentage of intact drug was \u226590%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Temocillin attained the chemical stability criterion of \u226590% of the original concentration for the whole experiment in both devices at 4\u00b0C, 25\u00b0C and 32\u00b0C. At 37\u00b0C, temocillin was stable for 24 h but its concentration dropped below 90% from that timepoint. No precipitation occurred and minor colour changes were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Temocillin is stable under OPAT conditions and it would be an appropriate candidate for the treatment of patients who can be discharged to complete therapy in an OPAT programme. For this study, an LC-MS\/MS method was developed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad251","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T04:22:36Z","timestamp":1691986956000},"page":"2451-2456","source":"Crossref","is-referenced-by-count":7,"title":["Stability of temocillin in outpatient parenteral antimicrobial therapy: is it a real option?"],"prefix":"10.1093","volume":"78","author":[{"given":"Beatriz","family":"Fern\u00e1ndez-Rubio","sequence":"first","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Hospital Universitario Virgen del Roc\u00edo\/Instituto de Biomedicina de Sevilla (IBiS) , Seville , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-944X","authenticated-orcid":false,"given":"Laura","family":"Herrera-Hidalgo","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Hospital Universitario Virgen del Roc\u00edo\/Instituto de Biomedicina de Sevilla (IBiS) , Seville , Spain"},{"name":"Unidad de Gesti\u00f3n Clinica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo\/Instituto de Biomedicina de Sevilla (IBiS) , Seville , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-527X","authenticated-orcid":false,"given":"Luis E","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Infectious Diseases and Microbiology Clinical Unit, University Hospital Virgen Macarena\/Instituto de Biomedicina de Sevilla (IBiS) , Seville , Spain"},{"name":"Departament of Medicine, School of Medicine, University of Sevilla , Seville , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Luque-M\u00e1rquez","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Clinica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo\/Instituto de Biomedicina de Sevilla (IBiS) , Seville , Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ar\u00edstides","family":"De Alarc\u00f3n","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Clinica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo\/Instituto de Biomedicina de Sevilla (IBiS) , Seville , Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Luque-Pardos","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Hospital del Mar , Barcelona , Spain"},{"name":"Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurora","family":"Fern\u00e1ndez-Polo","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Hospital Universitari Vall d\u2019Hebron , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Guti\u00e9rrez-Urb\u00f3n","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Complexo Hospitalario Universitario de A Coru\u00f1a , A Coru\u00f1a , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-9001","authenticated-orcid":false,"given":"Jes\u00fas","family":"Rodr\u00edguez-Ba\u00f1o","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Infectious Diseases and Microbiology Clinical Unit, University Hospital Virgen Macarena\/Instituto de Biomedicina de Sevilla (IBiS) , Seville , Spain"},{"name":"Departament of Medicine, School of Medicine, University of Sevilla , Seville , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Victoria","family":"Gil-Navarro","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Cl\u00ednica de Farmacia, Hospital Universitario Virgen del Roc\u00edo\/Instituto de Biomedicina de Sevilla (IBiS) , Seville , Spain"},{"name":"Unidad de Gesti\u00f3n Clinica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo\/Instituto de Biomedicina de Sevilla (IBiS) , Seville , Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-1574","authenticated-orcid":false,"given":"Alicia","family":"Guti\u00e9rrez-Valencia","sequence":"additional","affiliation":[{"name":"Unidad de Gesti\u00f3n Clinica de Enfermedades Infecciosas, Microbiolog\u00eda y Medicina Preventiva, Hospital Universitario Virgen del Roc\u00edo\/Instituto de Biomedicina de Sevilla (IBiS) , Seville , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"key":"2023100302085509300_dkad251-B1","doi-asserted-by":"crossref","first-page":"dlab005","DOI":"10.1093\/jacamr\/dlab005","article-title":"Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis","volume":"3","author":"Heard","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023100302085509300_dkad251-B2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/antibiotics11040493","article-title":"Temocillin: applications in antimicrobial stewardship as a potential carbapenem-sparing antibiotic","volume":"11","author":"Lupia","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2023100302085509300_dkad251-B3","doi-asserted-by":"crossref","first-page":"e0205221","DOI":"10.1128\/aac.02052-21","article-title":"Modelled target attainment after temocillin treatment in severe pneumonia: systemic and epithelial lining fluid pharmacokinetics of continuous versus intermittent infusions","volume":"66","author":"Layios","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023100302085509300_dkad251-B4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/fmb-2018-0316","article-title":"Temocillin: is this the right momentum for its global use?","volume":"14","author":"Balakrishnan","year":"2019","journal-title":"Future Microbiol"},{"key":"2023100302085509300_dkad251-B5","author":"EUCAST","year":"2023"},{"key":"2023100302085509300_dkad251-B6","doi-asserted-by":"crossref","first-page":"dlac132","DOI":"10.1093\/jacamr\/dlac132","article-title":"Real-life temocillin use in greater Paris area, effectiveness and risk factors for failure in infections caused by ESBL-producing Enterobacterales: a multicentre retrospective study","volume":"5","author":"Dinh","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"2023100302085509300_dkad251-B7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2023100302085509300_dkad251-B8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkm467","article-title":"Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection","volume":"61","author":"De Jongh","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2023100302085509300_dkad251-B9","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/jac\/dkaa248","article-title":"Monte Carlo simulation of temocillin 6","volume":"75","author":"Tsakris","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023100302085509300_dkad251-B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2013\/205910","article-title":"Outpatient parenteral antimicrobial therapy","volume":"24","author":"Laupland","year":"2013","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2023100302085509300_dkad251-B11","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.sapharm.2021.01.009","article-title":"Clinical benefits and costs of an outpatient parenteral antimicrobial therapy service","volume":"17","author":"Bugeja","year":"2021","journal-title":"Res Social Adm Pharm"},{"key":"2023100302085509300_dkad251-B12","doi-asserted-by":"crossref","first-page":"e049733","DOI":"10.1136\/bmjopen-2021-049733","article-title":"Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses","volume":"11","author":"Dimitrova","year":"2021","journal-title":"BMJ Open"},{"key":"2023100302085509300_dkad251-B13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s15010-020-01398-4","article-title":"Efficacy and safety of a Belgian tertiary care outpatient parenteral antimicrobial therapy (OPAT) program","volume":"48","author":"Quintens","year":"2020","journal-title":"Infection"},{"key":"2023100302085509300_dkad251-B14","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.3390\/pharmaceutics14112289","article-title":"Clinical efficacy of temocillin standard dosing in patients treated with outpatient antimicrobial therapy","volume":"14","author":"Van den Broucke","year":"2022","journal-title":"Pharmaceutics"},{"key":"2023100302085509300_dkad251-B15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023100302085509300_dkad251-B16","author":"FDA.","year":"2008"},{"key":"2023100302085509300_dkad251-B17","author":"NHS Pharmaceutical Research and Development Working Group","year":"2019"},{"key":"2023100302085509300_dkad251-B18","first-page":"2140","article-title":"Antimicrobial resistance (AMR) - a threat continues emerging in Covid-19 pandemic & role of antimicrobial stewardship programmes (ASPs)","volume":"72","author":"Nasrumminallah","year":"2022","journal-title":"J Pak Med Assoc"},{"key":"2023100302085509300_dkad251-B19","doi-asserted-by":"crossref","first-page":"dlac086","DOI":"10.1093\/jacamr\/dlac086","article-title":"Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study","volume":"4","author":"Oosterbos","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2023100302085509300_dkad251-B20","doi-asserted-by":"crossref","first-page":"e049481","DOI":"10.1136\/bmjopen-2021-049481","article-title":"Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTART\u00c9): protocol for a randomised, pragmatic trial","volume":"11","author":"Mar\u00edn-Cand\u00f3n","year":"2021","journal-title":"BMJ Open"},{"key":"2023100302085509300_dkad251-B21","first-page":"55","article-title":"Current status in outpatient parenteral antimicrobial therapy: a practical view","volume":"29","author":"Candel","year":"2016","journal-title":"Rev Esp Quimioter"},{"key":"2023100302085509300_dkad251-B22","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/cid\/ciy1052","article-title":". Next step, outpatient antimicrobial therapy programs as a tool of stewardship programs","volume":"68","author":"L\u00f3pez-Cort\u00e9s","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023100302085509300_dkad251-B23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.eimc.2011.05.007","article-title":"Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study","volume":"29","author":"Cervera","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2023100302085509300_dkad251-B24","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3390\/antibiotics11081124","article-title":"Successful integration of clinical pharmacists in an OPAT program: a real-life multidisciplinary circuit","volume":"11","author":"Ortonobes","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2023100302085509300_dkad251-B25","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/jac\/dkq229","article-title":"Long-term stability of temocillin in elastomeric pumps for outpatient antibiotic therapy in cystic fibrosis patients","volume":"65","author":"Carryn","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2023100302085509300_dkad251-B26","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1136\/ejhpharm-2022-003286","article-title":"Evaluation of the stability of temocillin in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy in accordance with the requirements of the UK NHS yellow cover document","volume":"30","author":"Sime","year":"2023","journal-title":"Eur J Hosp Pharm"},{"key":"2023100302085509300_dkad251-B27","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/antibiotics11040458","article-title":"Stability studies of 16 antibiotics for continuous infusion in intensive care units and for performing outpatient parenteral antimicrobial therapy","volume":"11","author":"Loeuille","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2023100302085509300_dkad251-B28","author":"emc"},{"key":"2023100302085509300_dkad251-B29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.medmal.2020.06.004","article-title":"Terms of use of outpatient parenteral antibiotic therapy","volume":"51","author":"Diamantis","year":"2021","journal-title":"Infect Dis Now"},{"key":"2023100302085509300_dkad251-B30","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/jac\/dkw582","article-title":"Antibiotic stability related to temperature variations in elastomeric pumps used for outpatient parenteral antimicrobial therapy (OPAT)","volume":"72","author":"Voumard","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023100302085509300_dkad251-B31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jppr.1422","article-title":"Extended duration infusion temperatures in the tropics: 2 (EDITT2)","volume":"48","author":"Perks","year":"2018","journal-title":"J Pharm Pract Res"},{"key":"2023100302085509300_dkad251-B32","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijantimicag.2018.05.001","article-title":"Continuous beta-lactam intravenous antibiotic infusions for outpatient parenteral antimicrobial therapy","volume":"52","author":"Habayeb","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023100302085509300_dkad251-B33","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/jcm11061551","article-title":"Clinical outcomes of an innovative cefazolin delivery program for MSSA infections in OPAT","volume":"11","author":"Herrera-Hidalgo","year":"2022","journal-title":"J Clin Med"},{"key":"2023100302085509300_dkad251-B34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijantimicag.2017.03.016","article-title":"Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service","volume":"51","author":"Durojaiye","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023100302085509300_dkad251-B35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.medmal.2020.10.019","article-title":"Home intravenous antibiotherapy and the proper use of elastomeric pumps: systematic review of the literature and proposals for improved use","volume":"51","author":"Diamantis","year":"2021","journal-title":"Infect Dis Now"},{"key":"2023100302085509300_dkad251-B36","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s10337-014-2741-6","article-title":"Analysis of temocillin and impurities by reversed phase liquid chromatography: development and validation of the method","volume":"77","author":"Kahsay","year":"2014","journal-title":"Chromatographia"},{"key":"2023100302085509300_dkad251-B37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpba.2013.12.002","article-title":"Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients","volume":"90","author":"Miranda Bastos","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"2023100302085509300_dkad251-B38","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1039\/an9840901209","article-title":"High-performance liquid chromatographic assay of temocillin and epimerisation of its diastereoisomers","volume":"109","author":"Bird","year":"1984","journal-title":"Analyst"},{"key":"2023100302085509300_dkad251-B39","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clinbiochem.2015.02.006","article-title":"Validation of a HPLC-MS\/MS assay for the determination of total and unbound concentration of temocillin in human serum","volume":"48","author":"Ngougni Pokem","year":"2015","journal-title":"Clin Biochem"},{"key":"2023100302085509300_dkad251-B40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2011.09.041","article-title":"Therapeutic drug monitoring and LC-MS\/MS","volume":"883\u2013884","author":"Adaway","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2023100302085509300_dkad251-B41","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/ejhpharm-2019-002093","article-title":"Ceftolozane\u2013tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study","volume":"27","author":"Raby","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"2023100302085509300_dkad251-B42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pharma.2011.09.004","article-title":"Long-term stability of temocillin in dextrose 5% and in sodium chloride 0.9% polyolefin bags at 5 \u00b1 3\u00b0C after freeze-thaw treatment","volume":"69","author":"Rolin","year":"2011","journal-title":"Ann Pharm Fr"},{"key":"2023100302085509300_dkad251-B43","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.2042-7158.1986.tb04485.x","article-title":"The degradation of temocillin, a 6 alpha-methoxypenicillin, and identification of the major degradation products","volume":"38","author":"Burton","year":"1986","journal-title":"J Pharm Pharmacol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/10\/2451\/51743397\/dkad251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/10\/2451\/51743397\/dkad251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:09:29Z","timestamp":1696298969000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/10\/2451\/7241929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,8,14]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad251","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,8,14]]}}}